SHANDONG FENGJIN PHARMACEUTICAL CO.,LTD.

Shandong Fengjin Pharmaceutical Co., Ltd.(herein after as Fengjin Pharmaceutical), a wholly-owned subsidiary invested by Shandong Fengjin Bio-pharmaceutical Co., Ltd., is mainly engaged in the research and development, production and sales of chemical APIs. Fengjin Pharmaceutical was founded in March 2019 with registered capital of 66 million RMB. The project is located at No. 777 of Jinniushan Road, Wuning subdistrict-office, Muping District, Yantai City, with a total investment of 620 million RMB, covering a total area of 180,000 square meters which is divided into three phases of construction. The first phase of the project covers an area of 53,333 square meters and construction area of 40,000 square meters with an investment of 220 million RMB. The construction of the project started in February 2020 and the main construction has been completed at present. It is expected to be completed in June 2023 and officially put into production in July 2023.Active ingredients: febuxostat, Rosuvastatin calcium, Ranvastinib mesylate, Sunitinib malate, Sorafenib toluenesulfonate, erotinib hydrochloride, tadalafil, telmisartan, calcium ketoate, polycresol sulfonal. Animal drug: aminopropyl hydrochloride. Intermediates and chemicals: diimidazole, dithiothreitol